FDA orders clinical hold on Targeted Genetics trial

Share this article:
The FDA has ordered a clinical hold on a Targeted Genetics clinical trial involving tgAAC94, an investigational therapy indicated for treating inflammatory arthritis. The hold came after one subject experienced a serious adverse event, but the company says there is insufficient information to draw conclusions as to the cause.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.